**Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion**

E M Egido, J Rodriguez-Gallardo, R A Silvestre and J Marco

Clínica Puerta de Hierro y Departamento de Fisiología, Universidad Autónoma de Madrid, Madrid, Spain

(Correspondence should be addressed to J Marco, Clínica Puerta de Hierro, Universidad Autónoma de Madrid, San Martín de Porres 4, 28035 Madrid, Spain; Email: jmarco@hpw.insalud.es)

**Abstract**

**Objective:** Ghrelin is a 28 amino acid residue peptide identified in both human and rat stomach and which acts as an endogenous ligand for the GH secretagogue receptor (GHS-R) and stimulates GH release. GHS-Rs are expressed in a number of tissues, including the pancreas, and ghrelin-like immunoreactivity is present in peripheral plasma, where its levels increase during fasting and decrease after food intake. The relationship between nutritional status and circulating ghrelin concentrations prompted us to investigate the effect of this peptide on pancreatic hormone secretion.

**Methods:** The study was performed in the isolated rat pancreas perfused in situ. Insulin, glucagon and somatostatin were measured by radioimmunoassay.

**Results:** Addition of 10 nM ghrelin to the perfusate significantly reduced the insulin response to the secretagogues glucose, arginine and carbachol, which act on the B-cell via different mechanisms, as well as the somatostatin response to arginine. Ghrelin was without effect on the glucagon output induced by this amino acid. At a lower concentration (2 nM) ghrelin was also found to inhibit glucose-induced insulin release.

**Conclusion:** These findings support the proposal that the inhibitory effect of ghrelin on insulin release constitutes a tonic regulation of the B-cell, contributing to restrain its secretory activity in the state of food deprivation. On the other hand, the inhibition of pancreatic somatostatin release by ghrelin suggests a blocking effect of this hormone on the widely distributed D-cell population.

**Introduction**

Ghrelin is a novel 28 amino acid residue peptide first identified in both human and rat stomach and which acts as an endogenous ligand for the growth hormone (GH) secretagogue receptor (GHS-R) and stimulates GH release (1, 2). GHS-Rs are expressed in both hypothalamus and pituitary (1, 3–5) as well as in the stomach (1, 4), intestine (1) and pancreas (1).

In the stomach, ghrelin is synthesized from preproghrelin in the A-like cells of the oxyntic mucosa (6), and ghrelin-like immunoreactivity has also been found in the small intestine, colon, rectum and pancreas (1, 6). Ghrelin-like immunoreactivity is present in human plasma, where its levels are reduced by food intake (7). Likewise, in the rat, circulating ghrelin increases during prolonged fasting and decreases upon re-feeding (6, 8, 9). Furthermore, it has recently been reported that circulating ghrelin levels are decreased in human obesity (10). These observations suggest a role for ghrelin in fuel homeostasis.

The present work was undertaken to examine the effects of rat ghrelin on insulin, glucagon and somatostatin secretion in the perfused rat pancreas.

**Materials and methods**

Male Wistar rats from our inbred colony (7–8 weeks of age, 200–225 g body weight) fed ad libitum were used as donors. Animals were maintained in accordance with the guidelines established by the European Union (86/609). After anesthesia of the rat with pentobarbital sodium (50 mg/kg, i.p.), the pancreas was dissected and perfused in situ according to the procedure of Leclercq-Meyer *et al.* (11) as adapted in our laboratory (12). Rat ghrelin (n-octanoylated), purchased from Peptides International (Louisville, KY, USA), was dissolved in 0.9% NaCl containing 0.1% bovine albumin (Cohn fraction V). This solution was prepared daily, immediately before experiments. When added to the perfusate, the final concentration was 2 or 10 nM ghrelin. Insulin secretion was stimulated by increasing...
the perfusate glucose concentration (from 5.5 to 9 mM), and by infusion of 10 mM L-arginine hydrochloride (Sigma, St Louis, MO, USA) or 1 μM carbachol (Sigma). Additions to the perfusate were performed as described in the corresponding figures. Glucagon and somatostatin were measured in some experiments. Insulin (13, 14), glucagon (15) and somatostatin (16) were analyzed by radioimmunoassay. Anti-pig insulin serum (I8510; Sigma) and rat insulin standards (Novo Nordisk, Bagsvaerd, Denmark) were employed. Anti-glucagon serum (04A) and anti-somatostatin serum (80 C) were kindly donated by R H Unger (University of Texas, Health Sciences Center, Dallas, TX, USA). Ghrelin did not cross-react with any of the antisera employed. The interassay variations were 5.6%, 7.8% and 6.4% for insulin, glucagon and somatostatin respectively, and the intra-assay variations were 4%, 5.6% and 4.6% respectively. Experiments were randomized and all samples for each series of perfusions were analyzed within the same assay. Results are expressed as the means±S.E.M. Hormone response was calculated as the integrated area of the curve above the mean pre-infusion level (average of all the baseline levels for each perfusion) employing the trapezoidal method. Statistical calculations were performed by analysis of variance and by Student’s t-test for unpaired samples.

Results

As shown in Fig. 1, addition of 10 nM ghrelin to the perfusate did not significantly modify basal insulin release (F10,50 = 0.54; not significant (n.s.)) but markedly inhibited the insulin response to increasing glucose concentrations (from 5.5 to 9 mM) (incremental area: 55±17 ng/15 min vs 107±13 ng/15 min in control experiments; P < 0.05). Figure 2 shows that ghrelin (10 nM) also blocked the insulin release elicited by 1 μM carbachol (incremental area: 18±5.6 ng/15 min vs 65±11 ng/15 min in control experiments; P < 0.01).

Figure 3 shows the effect of 10 nM ghrelin on the insulin, glucagon and somatostatin responses to 5 mM arginine. As depicted in Fig. 3A, ghrelin significantly reduced the second phase of the arginine-induced insulin release (incremental area: 78±16 ng/10 min vs 176±33 ng/10 min in control experiments; P < 0.05). As demonstrated in Fig. 3B, neither basal glucagon output (F10,80 = 1.24; n.s.) nor the glucagon response to arginine (incremental area: 14.1±3.1 ng/15 min vs 14.7±4.2 ng/15 min in control experiments; P = 0.91) were significantly modified by ghrelin. Figure 3C shows that 10 nM ghrelin significantly reduced the somatostatin response to arginine (incremental area: 627±327 pg/15 min vs 1530±225 pg/15 min in control perfusions; P < 0.05). Basal somatostatin release was not affected by ghrelin (F10,80 = 0.83; n.s.).

Finally, Fig. 4 shows that a lower ghrelin concentration (2 nM) significantly reduced glucose-induced insulin release (incremental area: 49±10 ng/15 min vs 104±12 ng/15 min in control experiments; P < 0.025).

Discussion

The foregoing results first demonstrate that, in the isolated rat pancreas, infusion of homologous ghrelin...
directly inhibits the insulin responses to glucose, arginine and carbachol, as well as the release of somatostatin evoked by arginine. Ghrelin was without effect on the glucagon output induced by this amino acid.

The perfused rat pancreas, while a suitable model to characterize the pancreatic hormone secretory pattern elicited by ghrelin, does not allow direct investigation of the detailed mechanism of action of this peptide. The inhibitory effect of ghrelin on insulin release elicited by secretagogues acting on the B-cell via different pathways may be due to a multifarious influence of this peptide on the B-cell stimulus–secretion coupling mechanism and/or a disturbing effect on a distal, crucial step in the insulin-releasing process, e.g. by affecting exocytosis. Given that ghrelin inhibits the insulin output evoked by carbachol, a substance acting on the B-cell by receptor-mediated activation of phospholipase C and stimulation of inositol phospholipid turnover (17), it can be inferred that this pathway, which plays an important role in B-cell secretion, is interfered with by ghrelin.

In apparent discrepancy with the anticholinergic effect of ghrelin we observed, Masuda et al. (18) have demonstrated that ghrelin stimulates gastric acid secretion as well as gastric acid motility by activating the vagal system. It should be stressed that, in our isolated pancreas model, islet cells are disconnected from the autonomous nervous system and, thus, the effect of ghrelin represents a direct influence on these cells.

Somatostatin has been shown to be an effective inhibitor of both insulin and glucagon secretion in a number of experimental conditions (19); thus, under ghrelin-induced suppression of somatostatin output, an increase in the secretory responses of these two hormones could be expected. However, the paracrine role of the D-cell in the control of B-cell and A-cell secretion is, in our opinion, not clearly elucidated. In fact, previous work from our laboratory, performed in the perfused rat pancreas, showed that in somatostatin-depleted pancreases, the absence of somatostatin release did not alter the normal insulin secretory pattern induced by various secretagogues (12).

Besides the inhibitory effect of ghrelin on pancreatic somatostatin release here described, Tolle et al. (20) demonstrated recently that addition of rat ghrelin to a preparation of perfused rat hypothalamic fragments significantly inhibited release of somatostatin induced by K⁺ depolarization, while basal somatostatin release was not modified under the same conditions. The latter finding is in accordance with the failure of

---

**Figure 3** Effect of 10 nM rat ghrelin on the insulin (A), glucagon (B) and somatostatin (C) responses to 10 mM arginine in the perfused rat pancreas. The solid line corresponds to control experiments: from 10 to 25 min, 10 mM arginine infusion (A, n = 5; B, n = 10; C, n = 8). The broken line corresponds to ghrelin experiments: from 0 to 10 min, ghrelin infusion at 5.5 mM glucose; from 10 to 25 min, 10 mM arginine + ghrelin infusion (A, n = 5; B, n = 9; C, n = 9). Values are means ± S.E.M.

**Figure 4** Effect of 2 nM rat ghrelin on the insulin response to increasing glucose concentration (from 5.5 to 9 mM) in the perfused rat pancreas. The solid line corresponds to control experiments: from 10 to 25 min, 9 mM glucose infusion (n = 9). The broken line corresponds to ghrelin experiments: from 0 to 10 min, 2 nM ghrelin infusion at 5.5 mM glucose; from 10 to 25 min, 9 mM glucose + 2 nM ghrelin infusion (n = 6). Values are means ± S.E.M.
gutropin to alter either unstimulated insulin or unstimulated somatostatin output. Taken together, these observations suggest that blockade of somatostatin secretion by gutropin might affect the D-cells widely distributed throughout tissues, an effect worthy of further investigation.

Information on circulating levels of gutropin is scarce. In humans, fasting plasma levels range from 0.1 to 0.25 nM (1, 7, 10) and, in fasted rats, values between 0.2 and 1 nM have been reported (4, 6, 9, 21). Moreover, two major molecular forms of gutropin, octanoylated and des-octanoylated, have been found in peripheral plasma, the latter of which does not activate GHS-R-expressing cells (21). Thus the octanoylated gutropin concentrations we tested (2 nM and 10 nM) should be considered pharmacological. However, gutropin-like immunoreactivity has been found in the pancreas (1, 8, 21) and, in addition to the gutropin reaching the B-cell through the systemic circulation, the local production of the hormone would augment its intra-islet concentration.

At present, conjecture about the implication of gutropin in the regulation of insulin secretion would be highly speculative. Given that plasma gutropin levels augment during fasting (6, 8, 9), it could be thought that the inhibitory effect of gutropin on insulin release constitutes a tonic regulation of the B-cell, contributing to restrain its secretory activity in the state of food deprivation. Conversely, the reduction of circulating levels of gutropin observed in human obesity (10) might contribute to the hyperinsulinemia characteristic of adiposity.

Acknowledgements

This work has been supported by grants from the Fondo de Investigación Sanitaria (FIS), Ministerio de Sanidad y Consumo (00/121) and from the Comunidad Autónoma de Madrid (8.6/0005/98), Spain. J R-G is a postdoctoral research fellow from the Comunidad Autónoma de Madrid, and E M E is a predoctoral fellow from the FIS. We thank M Messman for her secretarial help. The expert technical assistance of E Gutiérrez and P García is gratefully acknowledged.

References


Received 30 July 2001
Accepted 23 October 2001